Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Decreased by Cynosure Group LLC

Cynosure Group LLC lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,259 shares of the medical equipment provider’s stock after selling 1,287 shares during the quarter. Cynosure Group LLC’s holdings in Lantheus were worth $358,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LNTH. Farallon Capital Management LLC raised its stake in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after purchasing an additional 796,000 shares during the period. Dimensional Fund Advisors LP raised its position in Lantheus by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after buying an additional 19,071 shares during the period. Swedbank AB lifted its stake in Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after acquiring an additional 125,843 shares in the last quarter. Boston Partners boosted its position in Lantheus by 21.2% during the 1st quarter. Boston Partners now owns 681,281 shares of the medical equipment provider’s stock worth $42,696,000 after acquiring an additional 119,156 shares during the period. Finally, LSV Asset Management grew its stake in Lantheus by 27.9% during the 2nd quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock valued at $51,462,000 after acquiring an additional 139,647 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

LNTH has been the subject of several research reports. Truist Financial restated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Finally, JMP Securities reduced their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $90.27 on Friday. The stock has a market capitalization of $6.28 billion, a P/E ratio of 15.02 and a beta of 0.51. The business has a 50-day moving average of $102.12 and a two-hundred day moving average of $97.09. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.